MANDARA: Benralizumab v Mepolizumab in EGPA A#L14 #ACR23 @RheumNow P3, 52w RCT, 140 pts Remission rate: 59% Ben, 56.5%
Tweet Content
MANDARA: Benralizumab v Mepolizumab in EGPA
A#L14 #ACR23 @RheumNow
P3, 52w RCT, 140 pts
Remission rate: 59% Ben, 56.5% Mep
Relapse rate 30% in both
86% Ben, 74% Mep had reduction of GC dose 50%+, 41% v 26% tapered off
SAEs: 6% Ben, 13% Mep
Concl: Non-inferiority of Ben v Mep https://t.co/mSIFsDq8eL
Show on Archive Page
On
Display in Search Results
On
PDQ
Off